Last reviewed · How we verify

NCT05171673

Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants with Minor Soft Tissue Injury

Completed Phase 3 Last updated 10 December 2024
What this trial tests

Phase 3 trial testing Licart™ (diclofenac epolamine) topical system in Soft Tissue Injuries in 151 participants. Completed in 12 July 2024.

Timeline
31 October 2021
Primary endpoint
30 June 2024
12 July 2024

Quick facts

Lead sponsorIBSA Institut Biochimique SA
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment151
Start date31 October 2021
Primary completion30 June 2024
Estimated completion12 July 2024
Sites11 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

IBSA Institut Biochimique SA — full company profile →

Who can join

Adults 6 to 45, any sex, with Soft Tissue Injuries. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A multi-center, prospective, open-label, controlled study of the pharmacokinetics and safety of the LicartTM topical system in pediatric and adult participants with minor soft tissue injuries. 150 male and female participants aged 6-16 and 18-45 with soft tissue injuries meeting the following criteria will be enrolled to evaluate the pharmacokinetics and safety of the Licart topical system in pediatric and adult participants with minor soft tissue injuries over a 14-day treatment course. The analgesic effects will also be evaluated of the topical system in pediatric and adult participants with minor soft tissue injuries over a 14-day treatment course. To collect principal investigator-reported global response to therapy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Soft Tissue Injuries

Currently open trials in the same condition.

Other IBSA Institut Biochimique SA trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05171673.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing